Endothelial Cell Production of Nitrogen Oxides in Response to Interferon in Combination With Tumor Necrosis Factor, Interleukin-1, or Endotoxin
- 2 May 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 82 (9) , 772-776
- https://doi.org/10.1093/jnci/82.9.772
Abstract
Clinical studies using biological response modifiers in cancer therapy have shown that the major dose-limiting toxic effects are hypotension and diffuse microvascular leakage. The cause and pathophysiology of this hypotension remains unknown. Previous experiments have demonstrated that a number of cell types, including endothelial cells, neu-trophils, and macrophages, can secrete a potent hypotensive agent—endothelium-derived relaxing factor, which has recently been identified as nitric oxide. In this study, we tested interferon γ, tumor necrosis factor, interleukin-1, in-terleukin-2, muramyl dipeptide, and endotoxin for their effects on production of nitrogen oxides by endothelial cells. Interferon y, in combination with tumor necrosis factor, interleukin-1 (IL-1), or endotoxin, induced murine brain endothelial cells to secrete nitrites (20–45 μ M within 48 hr), which are breakdown products of nitric oxide. Nitrite production was blocked by incubation of endotheliai cells in medium without L-arginine, a substrate for nitric-oxide synthase. Accumulation of nitrites was also inhibited by addition of NG-monomethyl-L-arginine (l-NMMA), which acts as a competitive inhibitor of this enzyme. The inhibitory effects of l-NMMA were reversed by addition of excess L-arginine. These results suggest ( a ) that endothelial cells produce nitric oxide in response to immunomod-ulators and ( b ) that endothelial cell-derived nitric oxide plays a role in the development of hypotension in patients treated with tumor necrosis factor or interleukins. Furthermore, administration of substrate analogues such as l-NMMA may favorably alter the toxicity associated with these immunomodulators and result in a higher maximum tolerated dose, with subsequent improvement in the antitumor activity. J Natl Cancer Inst 82: 772–brief-report776, 1990]Keywords
This publication has 20 references indexed in Scilit:
- Nitric oxide: A cytotoxic activated macrophage effector moleculeBiochemical and Biophysical Research Communications, 1988
- Interleukin-1 and tumour necrosis factor cause hypotension in the conscious rabbitClinical Science, 1988
- L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxationBiochemical and Biophysical Research Communications, 1988
- Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species.The Journal of Immunology, 1987
- Superinduction of T lymphocyte-endothelial cell (EC) binding by treatment of EC with interleukin 1 and protein synthesis inhibitors.The Journal of Immunology, 1987
- Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.The Journal of Immunology, 1987
- Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.Proceedings of the National Academy of Sciences, 1986
- RECOMBINANT TUMOR-NECROSIS-FACTOR AND IMMUNE INTERFERON ACT SINGLY AND IN COMBINATION TO REORGANIZE HUMAN VASCULAR ENDOTHELIAL-CELL MONOLAYERS1986
- Prostacyclin Synthesis Induced in Vascular Cells by Interleukin-1Science, 1985
- Analysis of nitrate, nitrite, and [15N]nitrate in biological fluidsAnalytical Biochemistry, 1982